Asiatic acid as a bioactive pentacyclic triterpenoid scaffold: synthetic derivatization, structure-activity relationships, biological targets, and developability.
Abstract
Asiatic acid (AA) is an ursane-type pentacyclic triterpenoid from Centella asiatica with anticancer, anti-inflammatory, and neuroprotective activities reported in preclinical models. Its hydroxyl groups, polycyclic framework, and C-28 carboxyl group provide multiple sites for chemical modification, making it a useful scaffold for exploring relationships between molecular structure, biological activity, and developability. This review integrates synthetic derivatization, microbial transformation, structure-activity relationships, molecular mechanisms, delivery strategies, pharmacokinetics, and safety. C-28 esterification and amidation, A-ring oxidation and skeletal modification, C-23 functionalization, and pharmacophore conjugation have generated derivatives with altered activity and selectivity. Improvements reported in selected series depend on the substitution pattern, experimental model, and comparator, limiting generalization across studies. Mechanistic support also varies: some studies provide biochemical inhibition or experimental target engagement, whereas many proposed mechanisms remain supported mainly by cellular pathway responses or computational predictions. Evidence obtained with isolated AA is therefore distinguished from findings involving its derivatives, related triterpenoids, plant extracts, and multicomponent formulations. Lipid and polymeric carriers, hydrogels, microneedles, and inclusion complexes have improved formulation performance or exposure in selected preclinical settings, although the contribution of AA must be separated from carrier effects and other active ingredients. Poor aqueous solubility, low oral bioavailability reported in rats, heterogeneous study conditions, incomplete target validation, and insufficient data connecting exposure, efficacy, and toxicity remain development challenges. The review identifies priorities for AA optimization through matched structural comparisons, mechanistic validation, pharmacokinetic assessment, and safety evaluation, with candidate selection guided by reproducible pharmacological activity, achievable tissue exposure, and an acceptable therapeutic window.
Abstract as supplied by the indexing source. © the authors / publisher.